GHRP-2 on TikTok: separating hype from human data

What did @coach_mayhem actually say?

The creator claims GHRP-2 boosts growth hormone but also spikes prolactin and cortisol by acting on "the grayland receptor" in the brain. They suggest GHRP-2 raises cortisol more than GHRP-6 but less than "hexarillate," that prolactin elevation is mild at normal doses, and that cabergoline, P5P, or ashwagandha can manage side effects. They also position ipamorelin as a cleaner alternative with no prolactin or cortisol issues.

That is a lot of information packed into a short video. Some of it is directionally correct. Some of it is wrong in ways that matter. And the receptor name? That is just wrong.

Does the science back this up?

Partially. GHRP-2 does stimulate GH release and does elevate cortisol and prolactin to a measurable degree. The mechanism is real, just mislabeled. The comparative cortisol claim has some research support, and ipamorelin's cleaner hormonal profile is well-documented.

The receptor GHRP-2 binds is called the ghrelin receptor, formally known as the growth hormone secretagogue receptor type 1a (GHSR-1a). There is no such thing as a "grayland receptor." This is not a minor slip. The ghrelin receptor system is the core pharmacology of this entire peptide class. Korbonits et al. (2004, Frontiers in Neuroendocrinology) documented that GHRP-2 binds GHSR-1a with high affinity, triggering not just GH but also ACTH-driven cortisol and prolactin release from the pituitary. That downstream hormonal activation is real and clinically relevant.

On the cortisol comparison: Arvat et al. (2001, Journal of Clinical Endocrinology and Metabolism) showed GHRP-2 produces a more pronounced ACTH and cortisol response than GHRP-6 in healthy adults. That part of the video is accurate.

What did they get wrong (or right)?

The receptor name is wrong, full stop. "Grayland receptor" is not a term used anywhere in the pharmacological literature. Getting the receptor wrong matters because it shapes how someone understands dosing, interactions, and risks. That said, the functional description of what happens when that receptor is activated is roughly correct.

The cortisol hierarchy claim holds up. Compared to GHRP-6, GHRP-2 does appear to drive a stronger cortisol response. The comparison to hexarelin (which the creator calls "hexarillate") is also directionally supported. Loche et al. (1997, Journal of Endocrinology) found hexarelin produces a robust ACTH and cortisol elevation, generally considered stronger than GHRP-2's.

The ipamorelin claim is one of the more defensible things said in the video. Bowers et al. (1998, Endocrine) confirmed ipamorelin has high GH specificity with minimal effect on cortisol or prolactin, making it genuinely different from GHRP-2 in this respect.

The supplement mitigation advice is where things get shaky. Recommending cabergoline, a dopamine agonist with real side effects, as casual peptide co-medication is not something that should be handed out in a TikTok caption. Ashwagandha for cortisol control is speculative at best in this context.

What should you actually know?

GHRP-2 is an unregulated research compound in most countries. It is not FDA-approved for any indication. The hormonal effects the creator describes, including GH, cortisol, and prolactin changes, are real and not trivial. Cortisol elevation is not just a gym inconvenience. Chronic ACTH-driven cortisol elevation affects immune function, blood sugar, and sleep quality.

Prolactin elevation, even if mild, can affect libido, menstrual cycles, and potentially contribute to gynecomastia in men at higher doses. These are not things to manage with over-the-counter supplements based on a TikTok recommendation.

If you are considering any growth hormone secretagogue, that conversation should happen with a licensed clinician who can order baseline labs, including IGF-1, prolactin, and cortisol, and monitor for changes. Self-dosing based on social media content, regardless of how confidently it is delivered, carries real risk. No peptide in this class has robust long-term safety data in healthy adults.

Bottom line on this video

Credit where it is due: the broad strokes on GHRP-2's hormonal profile and ipamorelin's comparative cleanliness are grounded in real pharmacology. But the wrong receptor name, the casual recommendation of cabergoline, and the missing safety context make this a video that leaves viewers more confident than they should be. Confidence without accuracy is not the same as education.